Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 3/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15544746 | 1.00 | IDO1 (0.40) | IDO1ALDH1A1LMNAGAARECQL | |
| SCHEMBL15544702 | 0.89 | IDO1 (0.51) | IDO1ALDH1A1LMNAGAAAR | |
| SCHEMBL15544706 | 0.89 | IDO1 (0.51) | IDO1ALDH1A1LMNAGAAAR | |
| SCHEMBL18856836 | 0.85 | SMN1; SMN2 (0.32) | ALDH1A1BLM | |
| SCHEMBL15555645 | 0.83 | IDO1 (0.37) | IDO1ALDH1A1LMNAGAARECQL | |
| SCHEMBL15555643 | 0.83 | IDO1 (0.37) | IDO1ALDH1A1LMNAGAARECQL | |
| SCHEMBL15544496 | 0.82 | ALDH1A1 (0.49) | ALDH1A1LMNAGAARECQLKMT2A | |
| SCHEMBL15544492 | 0.82 | ALDH1A1 (0.49) | ALDH1A1LMNAGAARECQLKMT2A | |
| SCHEMBL15545116 | 0.82 | IDO1 (0.36) | IDO1ALDH1A1LMNAGAAKMT2A | |
| SCHEMBL15545119 | 0.82 | IDO1 (0.36) | IDO1ALDH1A1LMNAGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2870143-B1 | TRIAZOLE COMPOUNDS AS ANTIVIRALS | HOFFMANN LA ROCHE (CH) | 2017-05-17 | — | — | EP | disclosed |
| US-20150307461-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2015-10-29 | — | — | US | disclosed |
| EP-2870143-A1 | TRIAZOLE COMPOUNDS AS ANTIVIRALS | F. Hoffmann-La Roche AG (CH) | 2015-05-13 | — | — | EP | disclosed |
| US-20140010783-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2014-01-09 | — | — | US | disclosed |
| WO-2014006066-A1 | TRIAZOLE COMPOUNDS AS ANTIVIRALS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307461-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | IDO1 571/4885ALDH1A1 222/4885LMNA 3929/4885 |
| US-20140010783-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | IDO1 571/4885ALDH1A1 222/4885LMNA 3929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.